A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma

Clinical trial NCT07131501 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07131501
Sponsor: The First Affiliated Hospital with Nanjing Medical University
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Hepatocellular Carcinoma Immunotherapy Preoperative PD-1 CTLA-4

Start date: 2025-08-11
Primary completion: 2026-09-30
Enrollment: 48

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.